Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations

Table 6 Prevalence of the autoantibodies in the non-hepatocellular carcinoma and hepatocellular carcinoma chronic hepatitis B groups n (%)

	Non-HCC (n = 287)	HCC (n = 38)
	Pos.	Pos.	P value
ANA	68 (23.7)	8 (21.1)	0.718
SMA	10 (3.5)	0 (0.0)	0.613
AMA-M2	19 (6.6)	3 (7.9)	1.000
Anti-BPO	22 (7.7)	1 (2.6)	0.423
Anti-Sp100	8 (2.8)	0 (0.0)	0.603
Anti-PML	36 (12.5)	0 (0.0)	0.013
Anti-gp210	37 (12.9)	4 (10.5)	0.879
Anti-LKM-1	2 (0.7)	0 (0.0)	1.000
Anti-LC-1	10 (3.5)	0 (0.0)	0.613
Anti-SLA/LP	6 (2.1)	1 (2.6)	1.000
Anti-Ro52	82 (28.6)	9 (23.7)	0.528

ANA: Anti-nuclear antibodies; AMA: Anti-mitochondrial antibodies; SMA: Smooth-muscle antibodies; anti-PML: Anti-promyelocytic leukemia protein; anti-LKM-1: Anti-liver kidney microsome type 1; anti-LC-1: Anti-liver cytosolic antigen type 1; anti-SLA/LP: Anti-soluble liver antigen/liver pancreas.